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Abstract
Angiogenesis plays a crucial role in tumor growth and progression. Low expression of mineralocorticoid receptor (MR) in
several malignant tumors correlates with disease recurrence and overall survival. Previous studies have shown that MR
expression is decreased in colorectal cancer (CRC). Here we hypothesize that decreased MR expression can contribute to
angiogenesis and poor patient survival in colorectal malignancies. In a cohort of CRC patients, we analyzed tumor MR
expression, its correlation with tumor microvascular density and its impact on survival. Subsequently, we interrogated the
role of MR in angiogenesis in an in vitro model, based on the colon cancer cell line HCT116, ingenierized to re-express a
physiologically controlled MR. In CRC, decreased MR expression was associated with increased microvascular density and
poor patient survival. In pchMR transfected HCT116, aldosterone or natural serum steroids largely inhibited mRNA
expression levels of both VEGFA and its receptor 2/KDR. In CRC, MR activation may significantly decrease angiogenesis by
directly inhibiting dysregulated VEGFA and hypoxia-induced VEGFA mRNA expression. In addition, MR activation attenuates
the expression of the VEGF receptor 2/KDR, possibly dampening the activation of a VEGFA/KDR dependent signaling
pathway important for the survival of tumor cells under hypoxic conditions.
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Introduction
The mineralocorticoid receptor (MR) is a nuclear receptor that
has been classically associated to the control of ion transport in
epithelial cells, most notably in the kidney and colon. [1,2] This
specific activity plays a crucial role in regulating electrolyte
balance and blood pressure. However, it is now known that MR is
also expressed in cardiac myocytes, endothelial cells and neurons,
suggesting that it plays a physiological role in a large variety of
non-epithelial cells. [3,4] In classical mineralocorticoid target
tissues, MR resides mostly in the cytoplasm in an inactive state;
upon binding of physiological ligands such as aldosterone, MR
undergoes conformational changes, dissociates from molecular
chaperones and translocates into the nucleus where it regulates the
expression of target genes through specific DNA response
elements. [5] There is also evidence of the existence of non-
genomic mechanisms, by which activated MR interacts with
signaling pathway elements outside the cell nucleus to regulate
gene expression. [6] In all cases, the presence of different MR
isoforms, the existence of different ligand-induced post-transla-
tional modifications of the receptor and the recruitment of
different receptor-associated corepressors or coactivators may
account for cell-type specific effects of MR within different
mineralocorticoid target tissues. [7,8].
Many literature data indicate that aldosterone, through MR-
dependent mechanisms, may also mediate adverse effects on the
pathogenesis and progression of ischemic diseases in which
angiogenesis plays important role in the rescuing of hypoperfused
tissues. [9,10,11] Indeed, treatment with MR antagonists promotes
a faster and better revascularization reducing the extent of tissue
damage in ischemic limb, suggesting that aldosterone, via MR
activation, exerts a negative role on angiogenesis. This interpre-
tation is further supported by the finding that in this experimental
setting, MR inhibition also correlates with increased expression of
pro-angiogenic factors. [12] Moreover, aldosterone impairs
vascular regeneration by bone-marrow derived endothelial pro-
genitor cells, a process distinct from angiogenesis, relevant to
providing collateral source of blood flow in response to critical
narrowing of a major artery [13].
The delineation of molecular mechanisms of adaptive angio-
genesis in ischemic tissues has revealed a critical role of the
hypoxia-inducible factor-1 (HIF-1) in the transcriptional regula-
tion of genes coding for angiogenic growth factors that mediate the
re-growth of the vascular network. [14] In hypoxic cells, the
activation of the heterodimeric transcription factor HIF-1 is
mainly induced by the lack of the posttranslational modifications
of the alpha subunit (HIF-1a) by oxygen-dependent hydroxylase,
leading to its rapid degradation under normoxic conditions. As a
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consequence, under low oxygen concentrations, HIF-1a is
stabilized, heterodimerizes with the bsubunit HIF-1b) and binds
to hypoxia-response elements (HRE) in target genes [14].
Since a major feature of solid tumors is hypoxia, it is well
accepted that tumor elicits an angiogenic response mainly as a
result of a HIF-1a-driven increase in angiogenic factor expression,
even if dysregulation, due to intrinsic genetic mutations, must also
be taken into account. [15] Among different angiogenic growth
factors, secreted by both tumor and stromal cells and directly
regulated by HIF-1a, VEGFA plays a central role in promoting
neovascolarization in cancer. [16] More specifically, VEGFA has
been involved in colorectal cancer (CRC) progression, being
upregulated in patients with localized as well as metastatic CRC.
[17,18] VEGFA and other members of VEGF family bind to three
related membrane receptors (VEGFRs), namely VEGFR1/flt1,
VEGFR2/KDR and VEGFR3/flt4, with VEGF receptor 2/KDR
playing a pivotal role in mediating cell survival, mitogenesis and
differentiation of endothelial cells. VEGF receptor 2/KDR is also
expressed on human cancer cells, suggesting it may exert specific
roles. [19,20] Indeed, Calvani and collaborators provided
evidence that a VEGF/KDR/HIF-1a autocrine loop mediates
survival under hypoxic culture conditions of HCT116, a colon
cancer cell line [21].
A previous study reported that a decline of MR expression is an
early event in CRC progression and suggested that MR potentially
acts as a tumor-suppressor. [22] This notion is consistent with
recent reports that showed that, in lung tumors, MR expression
levels comparable to those found in normal lung tissue positively
correlate with patients overall survival time. [23] In addition, the
study in CRC showed that MR underexpression is associated with
VEGF receptor 2/KDR overexpression and suggested that
underexpression of MR may play a role in the pro-angiogenic
switch of the tumor. [22] However to date there has been no
mechanistic explanation to this correlation.
In the present study, we first investigated MR expression,
angiogenesis and patient survival in a cohort of patients with CRC
and demonstrated that decreased MR expression is correlated to
increased microvessel density (MVD) and to decreased survival of
the patient. We then used an in vitro system based on the colon
cancer cell line HCT116, genetically manipulated to express high
levels of functionally active MR, to test the hypothesis that MR
activation by agonists may negatively regulate tumor angiogenesis.
We demonstrated that aldosterone treatment of MR-transfected
HCT116 cells decreases the expression of VEGFA mRNA, in both
normoxic and hypoxic culture conditions. Moreover, we showed
that, in the same cells, aldosterone attenuates the expression of
VEGF receptor 2/KDR mRNA.
Materials and Methods
Ethics Statement
Thirty consecutive patients undergoing surgery for primary
sporadic colorectal cancer were included in the immunohisto-
chemistry and survival analyses. All patients were informed and
gave their written consent to the study and the anonymous use of
their data before being enrolled. The human study was approved
by the Ethics Committee of Spedali Civili of Brescia and the study
protocol was in accordance with the Declaration of Helsinki of
good clinical practice guidelines.
MR and CD34 Immunohistochemistry (IHC) and Survival
Analysis
Primary endpoints were tumor expression of MR and of CD34,
both evaluated by immunohistochemistry. The CD34 endothelial
marker was used in order to assess tumor microvessel density
(MVD). [24] The following variables were evaluated in order to
assess the correlation with the mentioned endpoints: age and
gender of patients, colonic site, stage, grade of differentiation,
mucinous subtype, and lymphovascular invasion of tumour, intent
and setting of primary treatment, overall 5-year survival. Samples
of tumour and normal colorectal mucosa were obtained from
formaldehyde-fixed surgical specimens. Paraffin sections were
stained with hematoxylin-eosin, PAS and PAS Diastase. For the
immunohistochemical evaluation the following antibodies were
employed: MR (Ab2774, dilution 1:250 AbCam, Cambridge,
UK), after pH6 citrate buffer treatment for 40 minutes and CD34
(CD34Ab1, dilution 1:30 Thermo Scientific, Astmoor Runcon,
UK) after 3 citrate buffer pH 6 cycles. The number of positive cells
was counted for each patient in 10 high power fields (HPF, x40) by
one pathologist (VV), and the results were categorised into three
levels of expression according to the proportion of positive cells;
MR expression: low or MR 1+: ,33%, intermediate or MR 2+:
between 33% and 67%, high or MR 3+: .67%, CD 34
expression: low CD34 1+,33%, intermediate or CD34 2+:
between 33% and 67%, high or CD34 3+:.67%.
Cells
The human colon cancer cell line HCT116 was a kind gift of Dr
G Melillo (National Cancer Institute, Frederick, MD, USA) [21].
Wild type HCT116 cells were maintained in RPMI with different
concentration of FCS, while transfected HCT116 cells were grown
in McCoy’s medium with different concentration of charcoal-
stripped FCS or FCS as described below.
Plasmids
PchMR, which expresses the hMR [25] and pFC31-luc which
expresses firefly luciferase under the control of tandem glucocor-
ticoid response element-containing mouse mammary tumor virus
promoter [26] were a kind gift from Dr ME Rafestin-Oblin
(INSERM U, Paris, France); pRL-TK which expresses the Renilla
luciferase under the control of herpes simplex virus thymidine
kinase promoter was purchased from Promega; pcDNA3 was
purchased from Invitrogen.
Transient Transfection
HCT116 were transfected using FuGENE HD Transfection
Reagent (Roche) according to the manufacturer’s instruction.
Transfection efficiency for pchMR was assessed at 24h after
transfection by immunohistochemistry and found to be 53.568%.
For an extensive description of this analysis, please see text S1.
Establishment of Hypoxia
Normoxia was maintained by growing cells at 37uC in a
humidified incubator containing 5% CO2 in air. Hypoxia was
established by maintaining culture flasks at 37uC under a constant
flow of an hypoxic gas mixture composed of 95% N2 and 5% CO2
for 90 min as described. [27] Then flasks were sealed and
incubated at 37uC for the desired time of hypoxia.
Culture and Treatment Conditions of pchMR-MR
Transfected HCT116 Cells Grown under Normoxia and
Hypoxia
Five hours after transfection with pchMR, HCT116 cells were
incubated in Mc Coy’s medium containing 10% hormone-free
Charcoal-Stripped Fetal Bovine Serum (Invitrogen) in air for 12 h
(normoxia experiments) or 24 h (hypoxia experiments or CoCl2
treatment). Cells were then treated with 3 nM aldosterone (Sigma-
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Aldrich) and/or spironolactone (1 mM, given 1 h prior to
aldosterone) (Sigma-Aldrich) and further incubated for 36 h in
air (normoxia), or exposed for 20 hours either to lower oxygen
(hypoxia) or to 100 mM CoCl2 treatment (CoCl2). Alternatively,
five hours after transfection with pchMR or pcDNA3, cells were
incubated in 10% FCS-supplemented medium for 48 hours in air
(normoxia) or incubated for 24 hours in air followed by exposure
to low oxygen for 20 h (hypoxia).
Quantitative RT-PCR
RNA was extracted and retrotranscribed as described. [28]
Transcript levels were analysed by real-time PCR in an iCycler
apparatus (Bio-Rad, Milan, I) with iQ SYBR Green Supermix
(Bio-Rad) under conditions recommended by the supplier. PCR
Primers, see Table S1, were obtained from Eurofins MWG
Operon. Messenger RNA expression levels were normalized to b-
actin by the Q-gene software application. [29] Each sample was
analyzed in triplicate and PCR products were also separated on
2.5% agarose gel for control.
Western Blot Analysis
For an extensive description, please see text S1. The following
antibodies were used for detection: anti-human MR (dilution
1:300, kindly donated by Dr Gomez-Sanchez, GV Sonny
Montgomery VA Medical Center, Jackson, MS, USA) [30],
anti-human HIF-1a (cod. 610658, dilution 1:800, BD Transduc-
tion Laboratories), anti-human GAPDH (sc-32233, dilution
1:5.000, Santa Cruz).
Gene Reporter Assay
For an extensive description, please see text S1 in online
supplement. PchMR- or pcDNA3- transfected cells were co-
transfected with plasmid containing reporter genes. For the
detection of MR-driven luciferase expression, pFC31-luc and
pRL-TK served as reporter or coreporter gene vector, respective-
ly. Results are given as normalized relative luciferase activity.
Immunofluorescence
For an extensive description, please see text S1 in online
supplement. Fixed cells were incubated with anti-MR antibody
(dilution 1:100) and with Alexa Fluor 448 goat anti-mouse IgG,
(Invitrogen). Cell nuclei were counterstained with DAPI. Cells
were imaged by the LSM confocal microscope (Zeiss).
Statistical Analysis
Summary statistics for continuous variables with non-normal
distribution (as evaluated by Kolmogorov-Smirnov tests) are
presented as medians, while normally distributed variables are
summarized as means 6 SEM. Group differences were analyzed
with Wilcoxon–Mann–Whitney, Student’s t-test or ANOVA
followed by Bonferroni t-test as appropriate. The correlation
between the expression of MR and CD34 was evaluated by
applying Cohen’s Kappa and Kramer’s Phi tests. The Kaplan-
Meier method and LogRank test were used to examine the effects
of different variables on overall survival. No multivariate analysis
was performed given the limited sample size and the low ratio of
events per variable. The statistical analysis has been performed
using the open source statistical package R. All statistical tests were
two-tailed and performed at p of 0.05.
Results
In Colorectal Carcinoma Patients the Expression of
Mineralocorticoid Receptor is Inversely Correlated to
Microvessel Density and Poor Prognosis
The baseline clinical characteristics and information on the 5-
years follow-up of the patient cohort included in the study are
summarised in Table S2.
Microvessel density, as evaluated by the expression of the
endothelial marker CD34, and MR expression were assessed by
IHC. A representative pattern of CD34 and MR expression in a
CRC sample compared to that of a normal colonic mucosa is
shown in Fig. 1B and 1A, respectively. Results from similar
analyses in tumor specimens from our patient cohort, based on the
determination of the proportion of both CD34 and MR positive
cells in the different members of this group, show that CD34
expression was low in 12 subjects, intermediate in 2 subjects, and
high in 16 subjects while MR expression was low in 17 subjects,
and high in 13 subjects (Fig. 1). There was a significant inverse
correlation between tumor expression of CD34 and tumor
expression of MR (Kramer Phi coefficient: 0.95, Cohen’s kappa:
20.844, p,0.001). The expressions of both CD34 and MR were
associated (directly with p,0.001, and inversely with p,0.001,
respectively) with tumor stage categorised into stage I and II as
opposed to stage III and IV. Among the other clinico-pathological
variables, none was statistically associated to CD34 or MR
expression.
By log rank test, the overall survival was found to be related to
the expression of CD34 (p = 0.006), to the expression of MR
(p= 0.021) (Fig. 2), and to the intent of treatment (p = 0.002). None
of the other clinico-pathologic variables was found to be associated
to overall survival, however the impact of tumor stage on survival
was at the limit of the range of significance (p= 0.054).
VEGFA and VEGFR2/KDR Expression is Inhibited by
Mineralocorticoid Receptor Activation in a Colon Cancer
Derived Cell Line
To analyse the role played by MR on angiogenesis in CRC and
in the light of the important role played by angiogenic factors
directly produced by tumor cells in tumorigenesis, we set up an
in vitro model by transfecting HCT116, a colon cancer cell line in
which endogenous MR protein level was barely detectable (Fig. 3A,
upper part), with an efficient MR gene expression system (pchMR
plasmid) [25].
We showed that at least 50% of HCT116 cells in culture could
be routinely transfected (see Material and Methods) and express MR
protein at significant levels, as shown by comparing them to
HEK293 cells, taken as a positive control (Fig. 3A, upper part).
[31] In addition, using different approaches, we showed that in
pchMR-transfected HCT116 cells MR is functionally activated by
agonists. Indeed, after the supply of aldosterone, MR underwent
specific post-translational modifications (Fig. 3A, lower panel), the
transcription of a MR reporter plasmid containing luciferase gene
was strongly enhanced (Fig. 3B), and MR was translocated into the
cell nucleus with the expected kinetics (Fig. 3C). In particular,
aldosterone given to the cells grown in medium supplied with
either 0.1% or 10% charcoal stripped fetal calf serum significantly
enhanced the levels of the luciferase activity (16 folds in
aldosterone-treated pchMR-transfected cells vs -untreated con-
trols). It should be noted that luciferase activity was also activated
by growing cells in 10% fetal calf serum which naturally contains
MR agonists, thus representing a more physiological condition (5
folds in pchMR-transfected versus pcDNA3-transfected cells)
MR Activity Attenuates VEGF/KDR Pathways in CRC
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(Fig. 3B). [32] Induction of luciferase activity by aldosterone
treatment, similar to what found in transfected cells under
normoxia, was also found in cells exposed to lower oxygen
concentration (Fig. 3B), allowing us to test the effect of MR
activation also in cells grown under hypoxic conditions. We also
showed that the competitive antagonist spironolactone caused the
disappearance of most of the aldosterone induced post-transla-
tional modifications while inducing by itself some other specific
ones (Fig. 3A lower panel) and largely, though incompletely,
abolished the increase of luciferase activity induced by aldosterone
(Fig. 3B). Strikingly, the nuclear translocation of MR induced by
aldosterone could not be blocked but rather was induced by
spironolactone alone (Fig. 3C).
Functional validation of our cell model allowed us to investigate
the possible causal relationship between MR activity and
expression changes of mRNA coding for different angiogenic
factors both in normoxic and hypoxic environment. We demon-
strated that, in pchMR-transfected HTC116 cells grown under
normoxic conditions, MR activation by aldosterone induces a
significant decrease in VEGF mRNA expression, while it does not
affect the mRNA expression levels of other angiogenic factors,
namely bFGF, PGF2 and EGF. The aldosterone-induced decrease
of VEGFA expression was specifically, albeit partially, inhibited by
Figure 1. IHC pattern of CD34 and Mineralorticoid Receptor expression in normal colonic mucosa (A) and colonic adenocarcinoma
(B) (A, left panel). Scattered vessels positive for CD34 in lamina propria. (x20) and (A right panel) Diffuse nuclear positivity for MR in crypts of
colonic mucosa. (x40). (B) H&E: Adenocarcinoma of the colon, moderately differentiated as shown by Haematoxylin-Eosin staining. CD34: Focal
positivity for CD34 in vessels present in the tumor. MR: Diffuse nuclear and cytoplasmatic positivity for MR in tumor cells. Magnification: (a), x10; (b),
x20; (c), x40.
doi:10.1371/journal.pone.0059410.g001
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the competitive MR antagonist spironolactone (Fig. 4). On the
whole, these data point out VEGFA as a pro-angiogenic gene
potentially regulated by MR activity.
It is well known that hypoxia, a constant characteristic of solid
tumor microenvironment, strongly induces VEGFA expression.
On these bases we analysed the effect of MR activation on
VEGFA expression levels under low oxygen concentration. At this
purpose, we first demonstrated that, in pchMR-transfected
HCT116 cells, the levels of VEGFA mRNA increase after their
exposure to hypoxia similarly to wild type HCT116 cells and that
the CoCl2 treatment, which mimics hypoxia, strongly increases
VEGFA mRNA expression in transfected cells (Fig. 5B and 5A,
respectively). We then demonstrated that the decrease of VEGFA
expression induced by aldosterone in pchMR-transfected
HCT116 cells during normoxia (Fig. 4A) was also found under
CoCl2 treatment or hypoxic culture conditions (Fig. 6A). These
results are particularly significant since we showed that both
hypoxia and CoCl2 treatment strongly increases VEGFA mRNA
expression (Fig. 4B). Moreover, we also show that MR activation
by the agonists naturally present in whole FCS is able to decrease
VEGFA mRNA expression both under normoxic and hypoxic
conditions (Fig. 6B ).
Finally, on the bases of recent reports by Calvani and
collaborators on the role of KDR expressed in HCT116 cells in
sustaining cell survival after exposure to prolonged hypoxia, we
analyzed, in pchMR transfected HCT116 cells, a possible causal
relationship between MR activity and KDR expression changes.
Indeed, these authors demonstrated that KDR mediates a late
VEGF-dependent induction of HIF-1a, leading to the autocrine
production of VEGFA, since they could inhibit both HIF-1a-
induction and survival of hypoxic HCT116 cells, with either anti-
VEGFA or anti-KDR antibodies. [21] Thus, as a preliminary
experiment, we demonstrated the presence of a functional VEGF/
KDR/HIF1a autocrine loop in our HCT116 cell line, by
reproducing the lack of the late induction of HIF-1a by VEGFA
antibodies in cells grown under hypoxic conditions (Fig. S1).
We then demonstrated that, in pchMR-transfected HCT116
cells, MR activation induced a significant decrease in the levels of
KDR mRNA. KDR mRNA expression was decreased in
aldosterone stimulated pchMR-transfected HCT116 cells to about
65% respect to their unstimulated controls (Fig. 7A) and even to a
greater extent in serum stimulated pchMR- transfected HTC116
compared to pcDNA3–transfected controls (Fig. 7B). Strikingly,
although spironolactone did not significantly modify KDR
expression levels, it appeared to reverse only in part the effects
of aldosterone treatment in pchMR-transfected HCT116 cells.
Indeed, even if a similar decrease in KDR expression was observed
in aldosterone- and spironolactone-aldosterone-treated cells as
compared to controls, in the latter case the decrease was not
statistically significant (Fig. 7A). Reasons that may account for
different spironolactone potency in reversing the effects elicited by
active MR on different targets or in different contexts will be
discussed below.
Discussion
Because previous studies have shown that MR expression is
down regulated in both colorectal and lung cancers, it has been
suggested that MR may act as a tumor-suppressor gene [23].
Here we establish a link between underexpression of MR,
decreased patient’s survival and upregulation of tumor angiogen-
esis in advanced cancer stage. Using an in vitro model based on a
colon carcinoma cell line, in which we forced MR expression, we
also provide the evidence that activated MR can attenuate the
expression of VEGFA and its receptor 2/KDR.
A link between MR expression and angiogenesis in CRC has
been previously suggested. [22] Here we demonstrate that the
extent of MR positive cells is inversely correlated to MVD in
tumor specimens, supporting the hypothesis that decreased MR
expression releases a repressing role exerted by MR on tumor
angiogenesis. To give insights on the role played by MR in CRC
angiogenesis, we showed that the re-expression of activated MR in
a colon cancer cell line, characterized by a quite low MR protein
level, thus mimicking a key feature present in CRC in vivo, leads
to a specific decrease in mRNA expression of VEGFA among
other angiogenic factor analyzed, in cells under normoxic culture
Figure 2. Overall survival stratified by CRC expression of CD34 (left), and CRC expression of MR (right)(Kaplan-Meyer method).
doi:10.1371/journal.pone.0059410.g002
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conditions. These data provide a direct demonstration of a
suppressive role of MR in tumor angiogenesis driven by the
malignant epithelium. It is noteworthy that our findings in colon
cells are consistent with the results of a recent study in a transgenic
mouse model showing that long-term in vivo MR overexpression,
in the presence of physiological amount of aldosterone, specifically
downregulated VEGFA gene expression in the heart [33].
Little is known about the regulation of angiogenic growth
factors in tissue under normoxic conditions. However it is well
accepted that physiological stimuli, other than hypoxia, including
Figure 3. Human mineralocorticoid receptor can be functionally activated in HCT116 cell line. (A, upper panel) MR expression. Whole
cell lysates from wild type and pchMR-transfected HCT116 cells were analysed by western blot using anti-MR antibodies. Human kidney cells
(HEK293) served as positive control. Human GAPDH was used as protein loading control. Representative fluorograms from two independent
experiments giving similar results are shown (A, bottom panel) MR post-translational modifications. PchMR-transfected HCT116 cells were treated
for 24 h with 3 nM aldosterone and/or 1 mM spironolactone in Mc Coy’s medium with 10% charcoal-stripped FCS. Whole cell lysates were analysed by
Western blot using anti-MR antibodies. MR post-translational modifications induced by aldosterone treatment are indicated by the upward shift in
the mobility of MR. A representative fluorogram from three independent experiments with superimposable results is shown (B) MR dependent
luciferase activity. PcDNA3-transfected (gray bars) or pchMR-transfected (white bars) HCT116 cells were transfected with pMMTV-Luc to express firefly
luciferase from an MR dependent promoter. Cell culture, aldosterone or spironolactone treatment and normoxia or hypoxia conditions are detailed in
Materials and Methods section. Values of firefly luciferase activity of aldosterone-stimulated pchMR-transfected cells in 10% stripped FCS or 0.1% FCS,
both in normoxic or hypoxic conditions, were compared to those of unstimulated pchMR-transfected control cells, set as 1. Values of firefly luciferase
activity of pchMR-transfected cells in 10% FCS were compared to that of pcDNA3-transfected control cells, set as 1. Results were expressed as Mean6
SEM (n= 4–6). **p,0.005 and ***p,0.001, vs control cells, #p,0.001 vs FCS- or aldosterone-treated cells, ANOVA followed by Bonferroni t-test or
Student t-test when appropriate. (C) MR subcellular localization. PchMR-transfected HCT116 cells treated with aldosterone (3 nM) and/or
spironolactone (1 mM) for 30 minutes and stained with an anti-MR antibody (green) and DAPI (blue). Images were taken with a confocal laser
scanning microscope.
doi:10.1371/journal.pone.0059410.g003
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growth factor activated signaling pathways, can also induce HIF-
1a activation and the consequent transcription of hypoxia-
inducible genes under non hypoxic conditions. [34] In addition
many genetic alterations present in cancer cells can directly
increase HIF-1a expression, leading to the activation of VEGFA
gene expression, independently from intratumoral hypoxia.
[14,35] These data provide the molecular mechanisms linking
specific genetic alterations present in cancer cells with increased
tumor vascularization. Based on these literature data and on our
results from the analysis of VEGFA mRNA expression in MR-
transfected colon cancer cells grown under normoxic conditions
upon activation by the relative agonists, we suggest that MR may
inhibit deregulated angiogenesis in CRC.
However, here we suggest that activated MR also dampens
hypoxia-regulated angiogenesis, which is crucial for tumor cells to
survive and proliferate in a hostile microenvironment and is a
critical determinant of the tumor progression. [36] Indeed we
demonstrated that re-expressed and agonist-activated MR reduced
VEGFA mRNA expression in colon cancer cells even when
maximally activated by their exposure to lower oxygen concen-
tration or CoCl2 treatment.
Figure 4. MR activation specifically decreases VEGFAmRNA expression levels in HCT116 cells. Effects of aldosterone on VEGFA (A), bFGF
(B), PGF2 (C) and EGF (D) mRNA levels in pchMR-transfected HCT116 cells under normoxic culture conditions. Cells were treated with 3 nM
aldosterone in 10% stripped FCS in the absence or in the presence of 1 mM spironolactone and the analysis of mRNA levels were performed by Real-
time PCR. For each panel, mRNA expression values of treated pchMR-transfected cells were compared to those of unstimulated pchMR-transfected
control cells, set as 1. Results are expressed as Mean6SEM (n= 3). *p,0.05 vs pchMR-transfected control cells, ANOVA followed by Bonferroni t-test.
doi:10.1371/journal.pone.0059410.g004
Figure 5. VEGFA mRNA induction during hypoxic response of
HCT116 cells. Real-time PCR analysis of VEGFA mRNA induction in
wild type HCT116 cells exposed to the indicated times of hypoxia (A)
and in pchMR-transfected HCT116 cells exposed to normoxia, hypoxia
or CoCl2 treatment (B). In panel A, values of VEGFA mRNA expression
for each sample were compared to that of time 0, set as 1. In panel B,
values of VEGF mRNA expression of pchMR-transfected cells exposed to
hypoxia or CoCl2 treatment were compared to that of pchMR-
transfected control cells exposed to normoxia, set as 1. Results are
expressed as Mean6SEM (n = 3–4). * p,0.05 ANOVA followed by
Bonferroni t-test.
doi:10.1371/journal.pone.0059410.g005
Figure 6. Hypoxia-induced VEGFA mRNA expression is de-
creased by MR activation in HCT116 cells. Real-time PCR analysis
of VEGFA mRNA induction in (A) pchMR-transfected HCT116 cells
treated with 3 nM aldosterone in the presence or in the absence of
1 mM spironolactone and exposed to CoCl2 treatment or hypoxia and
(B) pchMR- or pcDNA3-transfected HCT116 cells cultured with 10% FCS
alone under normoxic and hypoxic culture conditions. In panel A,
values of VEGFA mRNA expression for each sample were compared to
those of unstimulated pchMR-transfected control cells, set as 1. In panel
B, values of VEGF mRNA expression of serum-activated pchMR-
transfected cells were compared to those of pcDNA3-transfected
control cells, set as 1. Results are expressed as Mean6SEM (n= 3–4).
*p,0.05 vs pchMR-transfected control cells or pcDNA3-transfected
cells, ANOVA followed by Bonferroni t-test or Student t-test when
appropriate.
doi:10.1371/journal.pone.0059410.g006
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In addition, our findings that, in MR-transfected colon cancer
cells, KDR expression was significantly decreased by MR
activation indicated that activated MR can inhibit also the
expression of the receptor 2 of VEGFA, thus strengthening the
hypothesis of a causal relationship between MR underexpression
and KDR overexpression found in CRC by Di Fabio and
collaborators. [22] On the basis of their results, these authors
hypothesized that MR underexpression may play a role in the
proangiogenic switch of the tumor through the enhancement of
KDR expression. Here we suggest mechanistic insights on the role
of increased KDR in promoting colorectal tumorigenesis, other
than supporting angiogenesis. Indeed, it has been shown that
VEGFA binds to KDR expressed on colon cancer cells and,
through activation of specific KDR downstream signaling
pathways, leads to a late induction of HIF-1a, which in turn
mediates an autocrine production of VEGFA. This latter then acts
as an important survival factor in colon cancer cells when cultured
under conditions which mimics oxygen deprivation found in solid
tumors. [21] The involvement of VEGFA in mediating survival of
hypoxic cancer cells was surprising because VEGFA, mainly
produced by stromal infiltrating cells or by tumor cells and acting
in a paracrine way, was thought to be primarily a survival factor
for endothelial cells. [16] It is noteworthy, that a similar feed-back
mechanism of hypoxic response, based on an HIF-1a-driven
VEGFA-mediated autocrine loop, has been reported also in
endothelial cells and shown to exert an autonomous control on
chemotaxis, mitogenesis and survival of endothelial cells, thus
directly contributing to neo-vascularization in hypoxic tissues [37].
Strikingly our results on the role of activated MR in the
attenuation of the expression of KDR in MR-transfected colon
cancer cells, agree with similar data obtained in endothelial
progenitor cells and HUVEC. [13,38] When compared with our
results, the data obtained in HUVEC showed that KDR mRNA
was similarly down-regulated by aldosterone, although the
reduction was less pronounced (30% vs 40%) even if they used a
higher concentration of aldosterone (10 nM vs 3 nM).
An unexpected result in our study is the only very partial
efficacy of the competitive MR antagonist spironolactone in
reversing the repressive effect of aldosterone on the expression of
both VEGFA and its receptor KDR. Indeed, the quite similar
inhibitory effects of aldosterone seen in HUVEC were reversed to
the basal level with 10 mM eplerenone. [38] Beyond the obvious
differences related to the cellular systems and MR antagonists (and
their concentration), there are several possible explanations of this
discrepancy. First, in all tested in vitro systems spironolactone
effects counteracting MR activation appear to be virtually partial,
varying as a function of cells, protocols and process under
investigation. Second, the unique western blot signal pattern of
MR seen when spironolactone is given together with aldosterone
prompted us to speculate that the receptor functional activity
cannot be fully comparable to a negative control. The result of one
set-up experiment of this study is consistent with this view, since
spironolactone could not completely abrogate the aldosterone
induced luciferase increase. Since we kept fixed any parameter in
the other set-up tests but the culture conditions, these latter ones
also appear to influence the degree of spironolactone reversion.
Finally, aldosterone can produce rapid non genomic effects that
are basically insensitive to spironolactone. These are mediated by
classical MR associated to a membrane complex and, likely, a G-
protein coupled membrane receptor. [39] We do not know if the
fraction of MR kept in the HCT116 cytoplasm upon aldosterone
addition is simply a side effect of receptor overexpression or it does
have a functional meaning out of the nucleus. Other inhibitors,
such as RU28318, are needed to inhibit these membrane
associated complexes and could be tested to address this particular
item [40].
In conclusion, our in vivo and in vitro studies allowed us to
demonstrate that MR can negatively regulate colorectal tumori-
genesis. Using an original in vitro model based on a colon cancer
cell line ad hoc ingenierized to express high levels of agonist-
regulated MR, we showed that the expression of an active MR is
causally linked to a decrease in the expression of VEGFA, which
sustains angiogenesis, critical for growth and progression of solid
tumors in a hypoxic environment. In addition, we showed that the
expression of an active MR is causally related to the inhibition of
KDR expression, possibly leading to the dampening of a specific
VEGFA/KDR signal transduction pathway, driving angiogenesis
in endothelial cells under hypoxic condition, but exploited by
colon cancer cells to survive in a hypoxic environment.
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Figure S1 HIF-1a protein increases during hypoxic response of
HCT116 cells. Wild type HCT116 cells were cultured in RPMI
with 0.1% FCS and exposed to a hypoxia lasting 20 hours in the
presence or absence of 200 ng/ml of anti-VEGFA antibodies.
Whole cell lysates were analysed by Western blot using anti-HIF-
1a antibodies. GAPDH was used as protein loading control.
Representative fluorograms from three independent experiment
are shown.
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